COMMUNIQUÉS West-GlobeNewswire

Beyond Air® Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd.
10/03/2026
GARDEN CITY, N.Y., March 10, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of [...]
Piston Bio Announces FDA Alignment on PST-101 Development Program for Cancer-Related Apathy
10/03/2026
MORRISTOWN, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Piston Bio LLC, a clinical-stage biotechnology company developing therapeutics targeting neuroimmune mechanisms in cancer, today announced the completion of a Type B [...]
BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting
10/03/2026
PHILADELPHIA and VANCOUVER, British Columbia, March 10, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company [...]
Palvella Therapeutics Launches "BEYOND mLM" Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Leading Lymphatic, Vascular, and Dermatology Nonprofit Organizations
10/03/2026
BEYONDmLM.com campaign designed to educate, engage, and empower patients, caregivers , and healthcare professionals Campaign developed and launched in close collaboration with leading nonprofit organizations, including [...]
Kane Biotech Expands U.S. Commercial Footprint with Strategic Distribution Partnership
10/03/2026
Kane also signs U.S.-based contract sales agents WINNIPEG, Manitoba, March 10, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (Kane or the Company), transforming wound care with three FDA 510(k) cleared and two Health [...]
NMD Pharma late breaking oral presentation at the MDA Conference with top-line safety and efficacy data from SYNAPSE-CMT, an exploratory Phase 2a clinical study of ignaseclant in Charcot-Marie-Tooth disease Types 1 & 2
10/03/2026
NMD Pharma will also present an update on the ongoing SYNAPSE-MG Phase 2b clinical trial of ignaseclant in generalized myasthenia gravis Aarhus, Denmark, 10 March 2026 – NMD Pharma A/S, a clinical-stage biotechnology [...]
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026
10/03/2026
Received FDA clearance of Investigational New Drug application (IND) for PRT12396, mutant-selective JAK2V617F inhibitor in the first quarter of 2026 Phase 1 study of PRT12396 in patients with polycythemia vera and [...]
Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update
10/03/2026
- Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 - - Reauthorization of FDA’s Rare Pediatric [...]
Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation
10/03/2026
IRVINE, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to [...]
Apyx Medical Corporation Reports Fourth Quarter and Full Year 2025 Financial Results
10/03/2026
Reported record total revenue of $19.2 million in the fourth quarter of 2025 Scaling U.S. commercial launch of AYON Body Contouring System ™ (AYON) to meet strong market demand Expect FY2026 total revenue in the range [...]
Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
10/03/2026
RAP-219’s lead program demonstrated robust and consistent activity in patients with focal onset seizures (FOS) in Phase 2a trial; initiation of Phase 3 program expected in the second quarter of 2026 RAP- 219 epilepsy [...]
Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights
10/03/2026
CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $555 million and $1.9 billion for the fourth quarter and full year 2025, respectively Surpassed milestone of more than 10,000 patients [...]
Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference
10/03/2026
Interim observations from the Phase 2 TRAILHEAD study show continued improvement in handgrip strength, overall stability of elbow and shoulder strength in new dynamometry measurements Greater improvements in strength [...]
CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering
10/03/2026
ZUG, Switzerland and BOSTON, March 10, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics AG (Nasdaq: CRSP) (the “Company”) today announced its intention to offer, subject to market conditions and other factors, $350 million [...]
Guidelight Names Kelly Jones as Chief Growth Officer
10/03/2026
Mission-driven behavioral healthcare leader brings deep expertise in scaling access to high-quality, evidence-based care BOSTON, March 10, 2026 (GLOBE NEWSWIRE) -- Guidelight, a leader in evidence-based mental health [...]
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
10/03/2026
Initial clinical data for CLN-978 in SLE and RA confirmed for Q2 2026; repeat dosing data in RA confirmed for Q3 2026 Zipalertinib rolling NDA submission completed; enrollment of REZILIENT3 frontline study completed [...]
Vireo Growth Inc. to Release Fourth Quarter and Full Year 2025 Results on March 17, 2026
10/03/2026
MINNEAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Vireo Growth Inc. ("Vireo" or the "Company") (CSE: VREO; OTCQX: VREOF), today announced that it will release its financial results for its fourth quarter and full fiscal [...]
BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update
10/03/2026
BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies Increased focus on PD-L1 1 /VEGF-A bispecific [...]
BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030
10/03/2026
BioNTech continues to sharpen its strategic focus on the growing late-stage clinical pipeline spanning immunomodulator, ADC and mRNA candidates BioNTech co-founders Ugur Sahin and Özlem Türeci will establish an [...]

Pages